《盈利預喜》雲頂新耀-B(01952.HK)料去年收入按年最多增長8.8倍
雲頂新耀-B(01952.HK)發盈喜,預計去年總收入介乎約1.24億至1.26億元人民幣(下同),而2022年的總收入約為1,280萬元,即按年增長8.7至8.8倍。
公司指出,期內收入大幅增加,主要由於國家藥監局(NMPA)於去年3月批准Xerava(依拉環素)在中國用於治療成人患者複雜性腹腔內感染(cIAI)的新藥上市申請,並於去年7月在中國成功上市;以及Nefecon於去年10月在澳門獲得批准且於去年12月成功上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.